Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure

Pfizer will reorganize from two business units to three, creating a separate Consumer Healthcare unit alongside Innovative Medicines and Established Medicines. The changes will not be effective until the beginning of 2019.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.

Pfizer Inc. unveiled a new global business structure July 11 that will organize the company into three businesses versus the existing two, breaking out a separate consumer healthcare business. Most notably for pharma, the organization will include a new hospital medicines business within Innovative Health, and fold biosimilars into the innovative business as well.

The new hospital business unit will include anti-infectives and sterile injectables – which along with biosimilars had previously been managed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

More from Scrip